Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · IEX Real-Time Price · USD
2.400
-0.210 (-8.05%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Can-Fite BioPharma Revenue
In the year 2023, Can-Fite BioPharma had annual revenue of $743.00K, a decrease of -8.27%.
Revenue (ttm)
$743.00K
Revenue Growth
-12.90%
P/S Ratio
17.84
Revenue / Employee
$92,875
Employees
8
Market Cap
13.25M USD
Revenue Chart
* The company reports in ILS currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 743.00K | -67.00K | -8.27% |
Dec 31, 2022 | 810.00K | -43.00K | -5.04% |
Dec 31, 2021 | 853.00K | 90.00K | 11.80% |
Dec 31, 2020 | 763.00K | -1.27M | -62.45% |
Dec 31, 2019 | 2.03M | -1.79M | -46.81% |
Dec 31, 2018 | 3.82M | 3.03M | 384.16% |
Dec 31, 2017 | 789.00K | 624.00K | 378.18% |
Dec 31, 2016 | 165.00K | 3.00K | 1.85% |
Dec 31, 2015 | 162.00K | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Dec 31, 2011 | 481.95K | -231.93K | -32.49% |
Dec 31, 2010 | 713.88K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
China Jo-Jo Drugstores | 154.66M |
TRxADE HEALTH | 6.66M |
BIMI International Medical | 5.85M |
QT Imaging Holdings | 1.40M |
Talis Biomedical | 989.00K |
Talphera | 651.00K |
CANF News
- 4 days ago - Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix - Business Wire
- 8 days ago - Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver - Business Wire
- 22 days ago - Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study - Business Wire
- 27 days ago - Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study - Business Wire
- 4 weeks ago - Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases - Business Wire
- 5 weeks ago - Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024 - Business Wire
- 5 weeks ago - Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6 - Business Wire
- 7 weeks ago - Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study - Business Wire